Skip to content
Friday, November 13, 2026
Betora Connect

Individuals Discontinuing Weight-Loss Medications Put On Weight at a Quadrupled Rate Than Those on Conventional Diets

Image of medical injection and weighing machine
Obesity treatment involves long-term strategies.

A recent study reveals that patients who discontinue popular weight-loss injections like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who end conventional diet and exercise plans.

Findings released in a leading medical journal points out that while obese individuals can lose about a fifth of their body weight while on the medication, the mass comes back at an estimated rate of nearly a kilo each month after stopping.

"People buying these drugs should be informed of the risk of fast rebound weight gain when the treatment concludes," warns researcher Dr. Susan Jebb.

This pace of regain suggests a return to original weight within about one and a half years.

Weighing Treatments

The study, which looked at 37 of studies involving thousands of patients, contrasted the outcomes of these new drugs with other pills.

Researchers emphasize that people who lose weight through dieting generally see a slower weight regain—approximately 0.1 kg a month—once they finish.

Understanding the Quick Regain

Experts propose the way of the drugs accounts for the amplified regain.

These medications imitate a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.

"Artificially providing the hormone concentrations several times higher than normal may cause the system to generate a reduced amount of its endogenous hormone, and may also reduce sensitivity to its effects," said Dr. Adam Collins, a dietetics researcher.

"Stopping of this hormone supplement means hunger is unsuppressed, making overeating much more probable."

An Ongoing Condition?

Medical guidelines suggest the injections for people with obesity-related health risks, alongside prescribed diet and exercise modifications.

Many experts contend that, due to the likelihood of relapse, the therapy should be considered long-term.

This opinion is echoed by pharmaceutical companies, who say that the results "emphasize the long-term character of obesity," comparing it to managing diseases like diabetes.

User Accounts

People who have discontinued the jabs describe a sudden return of appetite.

"It felt as if a switch that goes on and you become starving," said an individual.

This difficulty is compounded if patients have not adopted lasting lifestyle or habit modifications during therapy.

Significant Interest

Survey data suggest that millions of people in the UK have used these injections in the last 12 months, with demand remaining high.

  • Adoption is greater among women than men.
  • The 40s and 50s demographic shows the greatest level of interest.
  • A large proportion access the drugs through private prescriptions rather than the NHS.

Finally, experts caution that while GLP-1 drugs are powerful agents for weight loss, they are not a magic cure and lasting health benefits likely depends on ongoing lifestyle changes.

EG
Written by

Emily Garrison

A tech journalist and digital strategist with over a decade of experience covering UK innovation and startup ecosystems.

Betora Connect

Type to search articles.